Showing results (41-50 of 67) with videos related to
Sort By:
Pageof 7
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.Journal of the National Cancer Institute|October 3, 2002
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodiesGordon C Jayson, Jamal Zweit, Alan Jackson, et al.The Lancet. Oncology|March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Jaap Verweij, Hans Gelderblom, et al.Cancer|May 10, 2022
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trialRick Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, et al.European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.European Urology|June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.Pageof 7